{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 61,
  "pageCount": 239,
  "prevPage": 60,
  "nextPage": 62,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses highlighted text to emphasize key accusations regarding the validity of the 10kHz frequency and the integrity of the clinical trial data.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/61",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-61",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Nevro knew about this and launched a disinformation campaign.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33b-013f5ff23742",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "The KOL stated that European implanters were skeptical of the US pivotal study's results, which came out in 2014. Nevro's HF device had launched in 2010 in Europe, achieving some minor sales and providing European doctors with years of real-world outcomes data unavailable in the US - which never matched the dramatic results claimed in the SENZA-RCT trial. He stated that Nevro \"launched a disinformation campaign\" in response to European implanters' incredulity at data from the US pivotal trial. He further characterized Nevro's 10kHz frequency – the core of its IP – as a meaningless gimmick in which he didn't believe.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42c2ac42-6663-40d3-8d5a-6a12034619a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.88,
        "x": 0.06,
        "y": 0.66
      },
      "kind": "quote",
      "text": "Nevro has tried to bash the study. Simon has consulted with Boston Scientific, so there's some of that. Boston didn't fund the trial and I believe the PROCO study. Nothing has convinced me to date that 10kHz is better than 1kHz.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ad9f005-b67f-49a4-9b35-ea0ecb873dcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.88,
        "x": 0.06,
        "y": 0.5
      },
      "kind": "quote",
      "text": "Nevro took 10kHz as a frequency and threw a dart at the wall. They chose it because they could get IP on it. 10kHz is not a magic number. The PROCO study by Simon Thompson shows that. It was a crossover study design that evaluated 1,4,7, and 10kHz stimulator frequencies. Each patient received each frequency for 2 to 4 weeks at a time and then rated their pain. Patients had no preference, suggesting there was no difference in pain relief by frequency.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "964d95a1-b97f-4aea-9d84-17cce033f99e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.88,
        "x": 0.06,
        "y": 0.39
      },
      "kind": "quote",
      "text": "European implanters scratched their heads and said that we've been using Nevro for 3 to 4 years and our experience is not like your Nevro pivotal study. I was at [redacted] and I mentioned to [redacted] that we were getting calls like this. Nevro knew about this and launched a disinformation campaign.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fca29a08-09f1-4fe2-b643-ca617e9884d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“European implanters scratched their heads and said that we’ve been using Nevro for 3 to 4 years and our experience is not like your Nevro pivotal study. I was at [redacted] and I mentioned to [redacted] that we were getting calls like this. Nevro knew about this and launched a disinformation campaign.” — KOL and key player in the SENZA-RCT pivotal trial",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33b-06ed41e79b4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Consultation call with expert",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7dc4123-f2e4-49bd-9cb5-489c4700e7dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "3. Trial investigators, KOL's, and ex-employees painted the SENZA pivotal study as a fraud",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d215447-9d7e-4bca-89a2-8c16c1b77ff6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c441b61d-ce2f-48d2-9ea7-8ec16e6cb6a8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "e8c2c9ce-9c62-4d87-9bbf-6061fec61e63",
      "evidence": "The slide explicitly frames the clinical trial as a fraud and the company's actions as a disinformation campaign.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}